Paradase Treatment

Paradase for the Treatment of Parainfluenza

Paradase is an investigational host directed antiviral which has shown strong in vitro antiviral activities against parainfluenza infection.

Under EIND’s, over 65 critically ill patients have been treated with Paradase

A phase 1 study in severe PIV infection has been completed

Paradase is in a randomized Phase 2 trial for the treatment of severe PIV infection

Paradase has the potential to receive breakthrough designation and or Fast Track approval for PIV indication

Treatment of severe PIV is a significant unmet medical need